



PRESS RELEASE

## Change in number of shares and votes in Moberg Pharma

**STOCKHOLM, June 30<sup>th</sup> 2017, Moberg Pharma AB (OMX: MOB). The number of shares and votes in Moberg Pharma AB (publ) ("Moberg Pharma") has increased by 28,920 in June 2017. Therefore, there are in total 17,440,762 shares and votes in the company as of June 30<sup>th</sup> 2017.**

The total number of shares and votes has increased as a result of 28,920 shares issued after exercise of warrants under Moberg Pharma's share-based incentive program. Due to the exercise of the warrants, the total number of shares and votes has increased by 28,920 from 17,411,842 to 17,440,762 and the share capital has increased by SEK 2,892 from SEK 1,741,184.20 to SEK 1,744,076.20.

**For additional information, please contact:**

Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail: [peter.wolpert@mobergpharma.se](mailto:peter.wolpert@mobergpharma.se)

Anna Ljung, CFO, telephone: +46 707 66 60 30, E-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

**About this information**

This information is such that Moberg Pharma AB (publ) is obliged to disclose pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. (CET) on June 30<sup>th</sup> 2017.

**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal<sup>®</sup>, Kerasal Nail<sup>®</sup>, Balmex<sup>®</sup>, New Skin<sup>®</sup>, Dermoplast<sup>®</sup>, Domeboro<sup>®</sup> and Fiber Choice<sup>®</sup>. Kerasal Nail<sup>®</sup> (Emtrix<sup>®</sup>, Zanmira<sup>®</sup> or Nalox<sup>™</sup> in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).